Ahead of FDA meeting, S.F. biotech's stock dips on questions about data analysis
April 06, 2021 at 17:59 PM EDT
The company's anemia drug for chronic kidney disease patients, which originally faced an FDA decision date in December, is set to be reviewed by a panel of experts.
